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Probiotics (live microbial food supplements) have been shown to be effective in allergic 
diseases, but the potential of probiotics for treatment of adult atopic dermatitis is not clear. 
The effect of probiotic Bifidobacterium breve (B. breve) for atopic dermatitis was assessed 
in this study.  A total of 24 patients were given either B. breve strain YY or a placebo for 
8 weeks.  Clinical severity was evaluated by using the severity scoring of atopic dermatitis 
and quality of life was assessed by Skindex-29-J.  In addition, blood and fecal samples were 
taken before and after the study.  The objective severity scoring for atopic dermatitis signif-
icantly improved in the probiotic group compared with the placebo group.  In the quality 
of life assessment, the total score showed significant improvement in the probiotic group. 
The proportion of B. breve in intestinal microflora was increased in the probiotic group. 
However, no significant change in thymus and activation-regulated chemokine (TARC/
CCL17), immunoglobulin E or the number of eosinophils was found.  Our results suggest 
that B. breve may be beneficial for the treatment of atopic dermatitis.  However, since the 
severity of disease symptoms in the placebo group at the beginning of the study was milder 
than those in the probiotic group because the number of patients in the present pilot study 
was relatively small, further study is needed to determine the clinical value of B. breve in 
adult patients with atopic dermatitis.
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self-control against causal and aggravating factors 
(Furue et al., 2009).  In 80% of patients, symptoms 
appear by the age of 5 and involve a genetic factor 
known as “atopic disposition.”  Recently, filaggrin 
deficiency is thought to be the major risk factor for 
AD sufferers (O’Regan et al., 2009).  In addition to 
diminished barrier function, environmental factors 
such as mites and house dust, perspiration, bacte-
ria or fungi, contact antigens, stress and food have 
been indicated as causal and aggravating factors. 
Physicians provide guidance regarding schemes 
Atopic dermatitis (AD) is characterized by an itchy 
rash that often appears on the face and neck, in the 
cubital fossa, and in the popliteal fossa, tending to 
flare up and spread throughout the body.  Patients 
with AD are also predisposed to other allergic 
diseases, including bronchial asthma and allergic 
rhinitis.  The basic treatment regimen consists of 
anti-inflammatory therapy focusing mainly on the 
use of topical steroids appropriate to disease sever-
ity and prevention of relapse or recrudescence after 
remission by placing an emphasis on skin care and 
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and efforts to alleviate those factors in daily life. 
Treatment does not aim at providing a complete 
cure but rather at controlling the disease on a level 
that causes less of a hindrance to the patient in 
daily life.
 From an epidemiological survey conducted 
in 1989, Strachan proposed the so-called “hygiene 
hypothesis” according to which “exposure to infec-
tions or unhygienic environments up to infancy 
reduces the subsequent onset of allergic diseases” 
(Strachan, 1989).  In fact, AD has been increasing 
in developed countries.  If, during infancy, some-
one is too clean and has too few opportunities to 
have contact with bacteria and viruses, helper T 
cells (Th cells) are not stimulated and, consequent-
ly, allergies increase.  That theory is easy to under-
stand and has been relatively accepted (Flöistrup et 
al., 2006).
 Probiotics are defined as “living microorgan-
isms and products containing microbial metabolites 
which, in vivo, affect the normal intestinal bacte-
rial flora by improving its balance, and which are 
consequently biologically beneficial” (Fuller, 1989; 
Salminen et al., 1998).  A large number of lactic 
acid-producing bacteria (such as Lactobacillus, 
Enterococcus, Streptococcus and Bifidobacterium) 
are used as probiotics.  Owing to their bactericidal 
and antiproliferative effects against pathogens, they 
primarily help regulate intestinal functions.  Sec-
ondly, they also have a stimulating effect on immu-
nity.
 In 2001, in a double-blind study, Kalliomäki 
et al. administered the lactic acid bacterium (LAB) 
Lactobacillus rhamnosus (L. rhamnosus) to 159 
pregnant women with an atopic disposition and 
their infants aged up to 6 months (Kalliomäki et 
al., 2001).  At the age of 2 years, the incidence of 
AD was significantly lower in the Lactobacillus-
treated group than in the placebo-treated group.  In 
a follow-up study, the frequency of AD was also 
low at 4 years of age in the Lactobacillus-treated 
group (Kalliomäki et al., 2003).  In a double-blind 
study, Kukkonen et al. administered 4 types of 
encapsulated probiotics (L. rhamnosus GG and 
LC705, Bifidobacterium breve (B. breve) and Pro-
pionibacterium freudenreichii ssp. Shermanii) to 
1,223 pregnant women with an atopic disposition. 
To the newborns of those women, 0.8 g of galac-
tooligosaccharide (a saccharide that helps the in-
testinal growth of LAB) or a placebo was added as 
a prebiotic and administered in addition to Lacto-
bacillus for 6 months after birth (Kukkonen et al., 
2008).  At 2 years of age, the incidence of AD was 
significantly lower in the probiotics-treated group 
than in the placebo-treated group.  Hattori et al. re-
ported an elevation of the percentage of Bifidobac-
terium of the intestines and an improvement of cu-
taneous symptoms after administration of B. breve 
to AD infants with low amounts of intestinal Bifi-
dobacterium (Hattori et al., 2003).  Intestinal flora 
have a great influence on whether Th cells become 
Th1 or Th2 type cells.  In hygienic environments, 
administration of probiotics to pregnant women 
and newborns promotes a healthy differentiation of 
naive T cells into Th1 cells during infancy and is 
considered useful in preventing and treating AD (He 
et al., 2001).
 Meanwhile, in adults who have passed beyond 
the period of body growth and who no longer show 
any major changes in the balance between Th1 and 
Th2 cells, improvement of AD symptoms by pro-
biotics has been hitherto considered difficult (Lee 
et al., 2008).  However, it has been reported that 
Bifidobacterium is present in a significantly low 
number in the intestinal flora of AD patients after 
infancy (Suzuki et al., 2008).  Among probiotics, 
Lactobacillus is often used as fermented milk for 
its excellent flavor.  In Japan, a fermented milk 
food has been developed based on live B. longum, 
which has a high fixation ratio in the intestines of 
adults and is excellent for regulation of the intesti-
nal functions; its antiallergic effect is being studied 
(Xiao et al., 2007; Iwabuchi et al., 2009).
 In the present study, B. breve was selected on 
the basis of a report that this organism develops 
dominantly in the intestines of healthy breast-fed 
infants but is present in low numbers in the intes-
tines of infants with AD, and because in addition 
to its regulatory effect on intestinal function, its 
immunoregulatory effect is potentially useful in 
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adult patients with AD.  Viable B. breve or placebo 
capsules were administered to 24 adult patients 
with AD in a double-blind manner.  Disease se-
verity was assessed using the severity scoring of 
AD (SCORAD) (Kunz et al., 1997); intestinal 
flora were examined through feces sampling, se-
rum markers such as serum immunoglobulin E 
(IgE) and plasma thymus and activation-regulated 
chemokine (TARC) levels were measured (Kaki-
numa et al., 2001), and skin-disease-specific qual-
ity of life (QOL) was evaluated exhaustively.
 
 
Subjects and Methods
 
The present study has been reviewed by the Ethical 
Review Board of Tottori University Hospital, and 
was conducted from January 2008 through May 
2009 after being approved on April 11, 2007 (Ap-
proval Number: 841).  Written voluntary agreement 
was obtained after a full explanation was provided 
to the subjects regarding research purposes and 
methods, prospective benefits and risks, and they 
understood that a lack of participation would not 
result in any disadvantage, that consent could be 
withdrawn at any time, and that their personal in-
formation would be protected.
 Twenty-four adult patients (8 men, 16 women; 
mean age: 30.2 ± 9.6 years), diagnosed according 
to the Guideline for Management of AD by the 
Japanese Dermatological Association (Furue et 
al., 2009), were selected as test subjects.  During 
the study, as a general rule, we decided to continue 
each participant’s pre-study treatment regimen.  
 Test meals for 24 subjects were randomly allo-
cated by the controller as follows: 16 subjects were 
given test sample A containing B. breve (B. breve-
administered group), and 8 subjects were given 
test sample B containing a placebo (control group). 
After sample allocation, the key code was kept by 
the controller.  The test was terminated once the 
prescribed number of participants was reached. 
(Test sample A:  capsules filled with a lyophilized 
powder of live B. breve strain YY.  Test sample B: 
capsules in which the Test sample A constituent 
was replaced with a placebo powder.  Test samples 
were provided by Tokiwa Pharmaceutical, Kobe, 
Japan). 
 The administered dose of B. breve was more 
than 20 billion per day (2.0 × 1010 colony forming 
unit).  Test sample A was formulated to contain 
more than 10 billion B. breve (1.0 × 1010 colony 
forming unit) per capsule.  The test samples were 
ingested as one capsule after breakfast and one 
after dinner.  The study period was 8 weeks. 
Dermatologists rapidly examined subjects’ symp-
toms before study initiation and 8 weeks after its 
completion.  Severity was assessed on the basis of 
SCORAD.
 Fecal sampling was performed and intraintes-
tinal bacterial flora was searched before study ini-
tiation and 8 weeks after its completion.  Naturally 
excreted feces collected by the subjects were im-
mediately chilled under anaerobic conditions and 
bacterial flora was searched for within 24 h (Calpis, 
Tokyo, Japan).
 Blood collection was performed before study 
initiation and 8 weeks after its completion; blood 
markers including serum IgE, eosinophils and 
plasma TARC were examined (Mitsubishi Chemi-
cal Medience, Tokyo).
 Skindex-29 is a measure using 29 items that 
can help determine health-related QOL associated 
with skin disease (Chren et al., 1997).  Before study 
initiation and after its completion, the skin disease-
specific QOL questionnaire Skindex-29-J (Japanese 
version) was completed (Fukuhara, 2004).
 Statistical analyses were conducted using 
SPSS software (SPSS 12.0J for Windows, SPSS, 
Chicago, IL).  For an intergroup comparison be-
tween the B. breve-administered group and the 
control group, Student’s t-test was performed for 
age, the chi-square test was performed for gender, 
Mann-Whitney’s U test was performed for the 
SCORAD, and the chi-square test was performed 
among disease-severity-based subgroups.  The cor-
relation between the objective SCORAD and each 
end-point (QOL according to the Skindex-29-J, 
Bifidobacterium in the intestinal flora and blood 
markers) was examined using Spearman’s rank 
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correlation coefficient.  For comparison within each 
group before initiation and after completion, the 
Wilcoxon ranked sum test was used for SCORAD, 
Skindex-29-J and enterobacteria search.  Student’s 
t-test was performed for blood tests.
 
 
Results
 
Regarding treatment circumstances, 18 patients 
used topical preparations (17 used steroids, 7 con-
comitantly received internal tacrolimus and 1 used 
Vaseline only) and 15 used orally administered 
medicines (anti-histamines).  During the study 
period, as a general rule, no pre-study treatment 
methods were changed.
 We examined the relationships between the 
objective SCORAD of all patients at study initia-
tion and at each end-point (Table 1).  Skindex-29-J, 
number of eosinophils, total IgE levels and plasma 
TARC levels showed significantly positive cor-
relations to the objective SCORAD.  In contrast, 
Bifidobacterium in the intestinal flora showed no 
correlation in terms of logarithmic number or rate 
of colonization.
 We compared the demographic attributes 
of the placebo and B. breve-administered group 
subjects (Table 2).  There were no differences for 
gender or age between the 8 subjects in the placebo 
group and the 16 subjects in the B. breve-admin-
istered group.  The average age of the test subjects 
was 30.2 years (range, 20–65 years).  However, the 
average placebo group SCORAD score was 25.7 
and the average B. breve-administered group SCO-
RAD score was 41.0.  Patients with high disease 
severity were present in significantly large numbers 
in the B. breve-administered group.  This is attrib-
utable to the fact that the study was not randomized 
according to disease severity.  All SCORAD values 
in the B. breve-administered group decreased after 
the study, and a statistically significant difference 
was found in the objective SCORAD and in B 
value, which is indicative of the extent of the rash 
(Table 3).  Meanwhile, the placebo group showed 
no change (Table 4).
 At the beginning of the study, no difference 
was found between instestinal flora in the feces of 
the B. breve-administered group and that of the 
placebo group.  Since fecal sampling could not 
be performed in one B. breve-administered group 
subject (for personal reasons), the subject was ex-
cluded; post-study analysis of the intestinal flora 
was conducted in only 15 B. breve-administered 
Table 2.  Demographics and clinical character-
istics of the subjects at the study initiation
 
     Variable Placebo B. breve P value†
     [n = 8] [n = 16]
 
Age (year)
   Mean 29.3   30.7  0.738
   Range 22 – 65  20 – 46
Gender 
   Number of males (%)  3 (37)   5 (31) 0.759 
   Number of females (%)  5 (63)  11 (69)
Race
   Asian (%) 100  100
SCORAD
   Total score  25.7   41.0  0.027*
   Objective SCORAD  21.8   33.7  0.016*
Severity of AD‡ 
   Mild, < 15.0   1    1  0.133
   Moderate, 15.0–40   7    9
   Severe, > 40.0   0    6
 
 AD, atopic dermatitis; B. breve, Bifidobacterium breve; 
SCORAD, severity scoring of atopic dermatitis.
† Student’s t-test, chi square or Mann-Whitney’s U test; 
*P < 0.05.
‡ Severity of AD based on objective SCORAD.
Table 1.  Correlation coefficient between evalua-
tion items at baseline
 Objective SCORAD
 rs P value
Skindex-29-J 0.547 0.006**
Bifidobacterium (log number) –0.066 0.758 
Bifidobacterium (%) –0.249 0.241
Eosinophil 0.465 0.022*
IgE (RIST) 0.585 0.003**
TARC 0.569 0.004** 
 IgE, immunoglobulin E; TARC, thymus and activation-
regulated chemokine; RIST, radio-immunosorbent test; 
rs, Spearman rank correlation coefficient; SCORAD, 
severity scoring of atopic dermatitis.
* P < 0.05, **P < 0.01.
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Table 3.  Change from baseline in the Bifidobacterium breve-administered group [n = 16]
 
                                   Variable Baseline Final P value†
 Mean ± SD Mean ± SD
 
SCORAD Total score 41.0  ± 18.0  35.3  ± 16.9  0.109 
 Objective SCORAD 33.7  ± 13.6  28.9  ± 14.0  0.034*
 A:  Extent criteria 28.3  ± 20.6  25.5  ± 23.4  0.437 
 B:  Intensity criteria  8.0  ±  2.9   6.8  ±  3.0  0.018*
 C:  Subjective symptoms  7.3  ±  5.9   6.3  ±  5.0  0.861 
Fecal microflora (log number) Total bacteria 10.36  ± 0.40‡ 10.43  ± 0.45‡ 0.362 
 Bifidobacterium  8.89  ± 2.57‡  9.79  ± 0.68‡ 0.060
 Clostridium lecithinase (+)  1.90  ± 2.29‡  1.49  ± 2.05‡ 0.208
 Enterobacteriaceae  7.31  ± 1.25‡  7.33  ± 1.01‡ 0.834
Fecal microflora (%) Bifidobacterium 22.11  ± 20.2‡ 36.39  ± 27.28‡ 0.031*
 Clostridium lecithinase (+)  0.00  ± 0.00‡  0.00  ±  0.00‡ 0.180
 Enterobacteriaceae  1.38  ± 3.13‡  0.46  ±  0.66‡ 0.400
Diagnostic marker Plasma TARC (pg/mL)  760.8  ± 1356.3   511.7 ± 1099.2  0.133
 Serum IgE (RIST) (IU/mL) 5694.6  ± 8087.0  5463.2 ± 8164.4  0.444
 Eosinophil (/µL)  528.8 ±  503.6   475.6 ±  426.1  0.418
QOL Skindex-29-J   40.0  ± 21.2   30.4  ± 14.1  0.019*
 Emotions  42.7  ± 23.9   32.3  ± 16.2  0.030*
 Symptoms  57.8  ± 25.8   44.6  ± 13.5  0.016*
 Functioning  27.5  ± 21.1   20.6  ± 15.6  0.087
 
 QOL, quality of life; RIST, radio-immunosorbent test; SCORAD, severity scoring of atopic dermatitis; TARC, thymus 
and activation-regulated chemokine.  
† Wilcoxon signed rank test or Student’s t-test; *P < 0.05. 
‡ n = 15.
Table 4.  Change from baseline in the placebo group [n = 8]
 
                                   Variable Baseline Final P value†
 Mean ± SD Mean ± SD
 
SCORAD Total score 25.7  ±  6.6  26.1  ± 12.1  0.866 
 Objective SCORAD 21.8  ±  6.8  21.1  ±  9.3  0.440
 A:  Extent criteria 14.9  ± 13.6  13.6  ± 12.0  0.292
 B:  Intensity criteria  5.4  ±  1.4   5.3  ±  2.1  0.888
 C:  Subjective symptoms 3.9  ±  2.0   5.0  ±  3.5  0.323
Fecal microflora (log number) Total bacteria 10.53 ± 0.33  10.61 ± 0.46  0.389 
 Bifidobacterium 9.88 ± 0.53   9.88 ± 0.71  0.866
 Clostridium lecithinase (+)  1.48 ± 2.08   2.06 ± 2.58  0.500
 Enterobacteriaceae  6.78  ± 1.33  7.29  ± 0.98 0.834
Fecal microflora (%) Bifidobacterium 29.93 ± 17.57  21.83 ± 13.43  0.123
 Clostridium lecithinase (+)  0.00 ±  0.00   0.00 ±  0.00  1.000
 Enterobacteriaceae  0.21 ±  0.36   0.61 ±  1.36  1.000
Diagnostic marker Plasma TARC (pg/mL)  179.3 ± 281.6  292.3 ± 577.4  0.332
 Serum IgE (RIST) (IU/mL) 699.4 ± 742.2  629.6 ± 605.0  0.250
 Eosinophil (/µL) 332.5 ± 364.1  336.3 ± 245.0  0.973
QOL Skindex-29-J   27.8 ± 14.8  24.9  ± 17.1  0.401
 Emotions  32.5 ± 21.3  30.9  ± 19.2  0.574
 Symptoms 39.7 ± 11.5  34.2  ± 19.1  0.527
 Functioning  16.8 ± 16.0  14.6  ± 17.7  0.600
 
 QOL, quality of life; RIST, radio-immunosorbent test; SCORAD, severity scoring of atopic dermatitis; TARC, thymus 
and activation-regulated chemokine.
† Wilcoxon signed rank test or Student’s t-test.
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group subjects (Table 3).  The logarithmic number 
of Bifidobacterium increased, and a remarkable 
and statistically significant increase in colonization 
rate was seen (Table 3).  Meanwhile, no change 
was observed in intestinal flora of the control group 
(Table 4).  On the other hand, no significant differ-
ence was found in blood variables after the study in 
either group.
 At study initiation, the Skindex-29-J score was 
40.0 in the B. breve-administered group and 27.8 
in the placebo group; likewise, there was also a 
difference in the Skindex-29-J score (Tables 3 and 
4).  Overall Skindex-29-J values decreased signifi-
cantly as a result of Bifidobacterium administra-
tion (Table 3).  Among the measured Skindex-29-J 
items (emotions, symptoms and functions), emo-
tions and symptoms also significantly decreased. 
Meanwhile, the Skindex-29-J of the placebo group 
showed no change (Table 4). 
 
 
Discussion
 
In 1899, Bifidobacterium was isolated from the 
feces of breast-fed children and was used as a pro-
biotic for the first time (Tissier, 1899).  While in the 
mother’s womb, human beings live in an aseptic 
environment, but by the 6th or 7th day after birth, 
Bifidobacterium accounts for as much as 95% of 
the enteric bacteria in infants’ intestines.  From 
then on, under the influence of various factors such 
as age, eating habits and stress, Bifidobacterium 
decreases to 15% in adults and < 1% in the elderly. 
Generally, LAB produce lactic acid by degrading 
sugar, but Bifidobacterium has strong bactericidal 
activity in addition to producing acetic acid.  Bi-
fidobacterium regulates intestinal function but, 
unlike LAB, it cannot grow in the presence of oxy-
gen; for that reason, it must be carefully processed.
 The predominant types of Bifidobacterium 
present in human intestines vary from B. breve 
in infants, B. longum in adults and B. adlescentis 
in the elderly (Mitsuoka, 2005).  Previous reports 
have also mentioned administration of B. breve via 
bottle-feeding to ensure the formation of normal 
intestinal bacterial flora in low-weight children 
(Akiyama et al., 1994).
 Although prevention of AD by administra-
tion of probiotics to mothers and infants has al-
ready been reported (Kalliomäki et al., 2003), 
most reports on the treatment of patients with AD 
by probiotics were based on studies in infants.  A 
randomized double-blind crossover study of a com-
bination of L. rhamnosus and L. reuteri in patients 
with childhood AD (average 5.2 years of age) was 
also reported (Rosenfeldt et al., 2003).  Cutaneous 
eruption size according to the SCORAD (A values) 
decreased significantly in probiotic-administered 
groups.  Meanwhile, only a few studies have con-
firmed the efficacy of probiotic administration in 
adult AD patients.  Roessler et al. recently reported 
that SCORAD scores tended to improve after ad-
ministration of L. paracasei and B. lactis to adult 
AD patients (Roessler et al., 2008).  In addition, 
an epidemiologic study reported that the number 
of Bifidobacterium was significantly lower in AD 
patients than in healthy subjects (Watanabe et al., 
2003).
 Therefore, in this study, we examined the effi-
cacy of administration of live encapsulated B. breve 
to adult AD patients.  Throughout the study period, 
we found no exacerbation of allergic symptoms or 
adverse reactions (digestive symptoms) caused by 
the administration of test meals, suggesting that 
live B. breve is safe for adult AD patients.  In addi-
tion to a significant decrease in objective SCORAD 
after administration of live B. breve, a significant 
decrease of the extent of cutaneous eruption (B 
value) was found as well as elevated Bifidobacte-
rium colonization rate in feces.  This also indicates 
that B. breve administration improves skin disease-
specific QOL of adult patients with AD.  However, 
blood tests showed no significant difference in 
TARC level, an AD blood variable.  Overall, the 
present study suggests that administration of live B. 
breve is a safe and useful adjuvant therapy for adult 
AD patients. 
 There are 2 types of Th cells:  those that in-
hibit allergy (Th1 cells) and those that promote 
allergy (Th2 cells).  Allergies do not occur when 
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the balance between Th1 and Th2 is preserved, but 
when Th2 dominates, allergies occur easily.  Neo-
natal T cells are naive but during an individual’s 
period of growth, they gradually differentiate into 
Th1 and Th2 cells.  Production of Th1 cells is 
facilitated by gram-positive bacteria, whereas pro-
duction of Th2 cells is facilitated by gram-negative 
bacteria (Takeuchi et al., 1999).  In the differentia-
tion process, dendritic cells are stimulated through 
Toll-like receptors (TLR, membrane protein recep-
tors that activate intracellular transcription factors 
such as NF- B) when molecules derived from 
viruses or bacteria are present.  The probiotic LAB 
is a gram-positive bacterium that stimulates TLR2, 
which recognizes peptidoglycans in gram-positive 
bacteria and causes the differentiation of naive T 
cells into Th1 cells.  In sterile environments where 
TLR are not stimulated, naive T cells differentiate 
into Th2 cells.  In a clean environment, B. breve 
is thought to promote differentiation of naive T 
cells to Th1 during infancy.  In addition, stimula-
tion with B. breve causes maturation of dendritic 
cells and an increase of immunosuppressive IL-
10 through TLR2 (Hoarau et al., 2006).  It is from 
B. breve (the major portion of intestinal flora) that 
healthy infants receive the stimulation required for 
immune cell maturation during early childhood. 
In contrast, it can be hypothesized that B. breve is 
absent in children with AD, resulting in insufficient 
stimulation.
 In a double-blind, placebo-controlled trial us-
ing yogurt containing B. longum on adult patients 
with pollen allergy, the B. longum-administered 
group showed significant improvement of symp-
toms and significant inhibition of increased TARC 
levels (Xiao et al., 2007; Iwabuchi et al., 2009). 
Even in adults, Bifidobacterium is suggested to 
improve the balance between Th1/Th2 when domi-
nated by the Th1 side.  In experiments conducted 
on mice orally administered B. breve, allergy-
induced increases in IgE levels were inhibited, IL-4 
was significantly inhibited, and, consequently, Th2 
cell proliferation was suppressed, suggesting that 
the balance between Th1/Th2 might have shifted to 
the Th1 side (Inoue et al., 2009).  Recently, a com-
parative study of 6 different types of Lactobacillus 
with potential antiallergic properties was conducted 
on oval albumin-sensitized BALB/c mice.  As a 
result, it was concluded that B. breve was the most 
promising probiotic (Hougee et al., 2010).
 In adult AD patients, whose Th cells are 
already mature, the improving effect of B. breve 
might be difficult to explain in terms of Th1/Th2 
balance alone.  Recently, other T-helper cell subsets 
that differentiate from naive T cells have attracted 
attention as clues to immunostimulatory activity 
phenomena that cannot be explained by Th1/Th2 
balance.  Typical examples include regulatory T 
cells, which release the immunodepressive cytokine 
IL-10 (Sakaguchi, 2000), and Th17 cells, which 
release the inflammatory cytokine IL-17 (Weaver 
et al., 2006).  Recent probiotic research has also re-
ported that the LAB L. casei increases IL-10 secre-
tion from regulatory T cells (Hacini-Rachinel et al., 
2009) and that B. infantis has an inhibitory effect 
on Th17 (Tanabe et al., 2008).  It might have been 
through this kind of immunoregulatory effect that 
B. breve improved adult AD symptoms.
 In conclusion, we conducted a study of 
B. breve administration on adult AD patients. 
Through exhaustive evaluation of cutaneous symp-
tom severity, intestinal flora detected in the feces, 
blood allergy indicators, and patients’ psychologi-
cal status (QOL), we found that cutaneous symp-
toms improved, the share of Bifidobacteria in the 
feces increased significantly, and skin disease-
specific patient QOL improved significantly.  The 
above results suggest that administration of B. 
breve might be a useful adjuvant therapy for adult 
AD.  However, the severity of disease symptom in 
the placebo group was milder than that in the pro-
biotic group because the number of patients in the 
present pilot study was relatively small.  We plan to 
perform further large study in order to determine 
the definite clinical value of B. breve in adult pa-
tients with AD.
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